BioWorld® - Medical Device Daily

BioWorld Industrial Biotechnology StatReport: Immediate and Comprehensive Industry Information
Dyax Corp. antibody phage-display
libraries for the
discovery of human
GelTex
Pharmaceuticals
Inc.
Imperial Cancer
Research Fund
(ICRF)
antibodies
RenaGel phosphate
binder
gene therapies for
cancer
Institut Merieux glucocerebrosidase
(GCR) products to treat
IntroGene BV
(Netherlands)
Johns Hopkins
University School
of Medicine
Kaken
Pharmaceutical
Co. Ltd.
Gaucher's disease
gene therapy for
Gaucher's disease
cardiovascular gene
therapy
Seprafilm and
Sepracoat for
prevention of post-
operative adhesions
LeukoSite Inc. drug candidates for
treating autoimmune
and inflammatory
diseases
Macrozyme Corp. exploration of
applications of
Macrozyme's small
Mass General
Hospital
molecule library
gene therapy
treatments for chronic
hepatitis B and liver
cancer
license and
research
agreement
development and
commercialization
agreement--
Genzyme to pay
GelTex up to
$27.5M upon FDA
approval of product
development
agreement
technology license
and supply
agreement
licensing
agreement--
Genzyme to make
equity investment
and provide
research,
milestone, and
royalty payments
devleopment
collaboration
marketing
agreement for
Japan
screening
agreement--
LeukoSite will have
access to more
than 800K
compounds in
Genzyme's library
and will screen
against its
biological targets
related to cell
adhesion and
inflammatory bowel
disease; after
screening is
complete,
companies will
negotiate research
collaboration
covering
development and
commercialization
of compounds
discovered in
screening
exclusive
collaboration
development
collaboration
Copyright ©2006 AHC Media ® 178
6/04
6/97
1/96
9/89
10/94
5/98
2/97
6/97
11/05
6/97